Background: Maternal group B streptococcus (GBS) infection is associated with substantial risk of preterm birth and infant mortality. Preventative approaches to protect infants from GBS infection are needed.
Methods: In this phase 2b, randomized study, healthy nonpregnant 18-49-year-old females were randomized 1:1:1 to receive the investigational 6-valent GBS polysaccharide conjugate vaccine (GBS6) and concomitant Tdap (GBS6+Tdap), GBS6 and placebo (GBS6+placebo), or Tdap and placebo (Tdap+placebo). Primary safety endpoints included reactogenicity events within 7 days and adverse events (AEs) through 1 month after vaccination. Primary immunogenicity objectives were to describe immune responses induced by GBS6+Tdap versus Tdap+placebo and versus GBS6+placebo for pertussis, tetanus, and diphtheria Tdap antigens and the 6 GBS6 antigens.
Results: Overall, 304 participants received study vaccination. Most reactogenicity events were mild or moderate in severity and balanced across vaccine groups. Frequency of AEs was ≤8.1% across vaccine groups. One-month after vaccination, the proportion of participants achieving antibody concentrations ≥0.1 IU/mL, for tetanus and diphtheria antigens was 100% in both GBS6+Tdap and Tdap+placebo groups. Immune responses to pertussis antigens were lower in the GBS6+Tdap group compared to the Tdap+placebo group, with geometric mean ratios <0.6. No consistent effect on immune responses against each of the GBS6 serotypes after concomitant administration with Tdap was observed.
Conclusions: GBS6 and Tdap administered concomitantly and alone were safe and well tolerated in healthy nonpregnant individuals. Similar immune responses were observed for Tdap when administered with GBS6 or when administered alone. These results will likely inform future studies in pregnant individuals. (NCT04766086).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/infdis/jiaf096 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acellular Pertussis Vaccine Given in the Week After Birth Does Not Impair Antibody Responses to Later Childhood Doses.
Pediatr Infect Dis J
March 2025
National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia.
Background: A birth acellular pertussis vaccine may be a valuable alternative for immunity against infant pertussis when a pregnancy pertussis vaccine has not been administered. We assessed whether a birth dose may impair immunoglobulin G (IgG) responses to childhood pertussis boosters.
Methods: Children from our previous randomized controlled trial who received a monovalent 3-component aP and hepatitis B vaccine at birth (aP group) or hepatitis B only (control group) followed by Infanrix hexa at 2, 4 and 6 months of age were randomized to receive either high or low-dose diphtheria-tetanus acellular pertussis combination vaccine (DTPa-Infanrix/dTpa-Boostrix) at 18 months and 4 years of age.
Prevalence and associated factors of immunization among under-five children in Somalia.
BMC Public Health
March 2025
Quality Assurance, University of Hargeisa, Hargeisa, Somalia.
Background: Children worldwide can live lives free from various illnesses and disabilities due to vaccination. For instance, vaccination has eliminated smallpox, a deformative and frequently fatal illness that claimed an estimated 300 million lives in the twentieth century. However, due to a lack of access to immunization and other health services, 14.
View Article and Find Full Text PDFAssessing the geographic and socioeconomic determinants of vaccine coverage in Ethiopia: A spatial and multistage analysis at the district level.
Vaccine
March 2025
Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA. Electronic address:
Background: Despite substantial progress over the past decades, many Ethiopian children still lack the full WHO-recommended immunization schedule. Notably, diphtheria-pertussis-tetanus-Hib-HepB and measles vaccines present large coverage disparities in Ethiopia. This study integrated routine, survey and census data from health, geographic and socioeconomic sources at the district level.
View Article and Find Full Text PDFAssociated factors for dropout of first versus third doses of pentavalent vaccination in Tanzania.
Vaccine
March 2025
Ifakara Health Institute, Dar es Salaam, Tanzania. Electronic address:
The pentavalent is a vaccine against Diphtheria, Pertussis, Tetanus, Hepatitis B, and Haemophilus type B influenza. A child is considered a pentavalent vaccination dropout if they have received the first dosage as advised but have not obtained the third dose. In Tanzania, the first-dose receiver of pentavalent was approximately 97 %, whereas only 89 % received a third dose.
View Article and Find Full Text PDFHow to improve pertussis vaccination in pregnancy: a European expert review.
Expert Rev Vaccines
March 2025
Centre for the Evaluation of Vaccination, Vaccinopolis, University of Antwerp, Wilrijk, Belgium.
Introduction: Pertussis vaccination in pregnancy is a safe and highly effective strategy to protect young infants against severe pertussis, but cases continue to occur. In November 2023, the authors of this paper met to discuss difficulties faced by pertussis vaccination programs in pregnant women in Europe, and the need and potential for new vaccines.
Areas Covered: We summarize current pertussis epidemiology, the status of pertussis vaccination in pregnancy in Europe, followed by a summary of the meeting on benefits of pertussis-only vaccines and pertussis vaccines with improved immunogenicity, including a review of available vaccines.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!